DAIHAN PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28,100 KRW | +0.36% |
|
+0.54% | +1.26% |
| 2023 | Daihan Pharmaceutical Co.,Ltd.(KOSDAQ:A023910) dropped from S&P Global BMI Index | CI |
| 2023 | Daihan Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| Sales 2024 * | 213B 155M | Sales 2025 * | 233B 169M | Capitalization | 165B 120M |
|---|---|---|---|---|---|
| Net income 2024 * | 30B 21.78M | Net income 2025 * | 33B 23.96M | EV / Sales 2024 * | 0.13 x |
| Net cash position 2024 * | 138B 100M | Net cash position 2025 * | 163B 118M | EV / Sales 2025 * | 0.01 x |
| P/E ratio 2024 * |
5.48
x | P/E ratio 2025 * |
5.08
x | Employees | 553 |
| Yield 2024 * |
2.49% | Yield 2025 * |
2.58% | Free-Float | 59.32% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.36% | ||
| 1 week | +0.54% | ||
| Current month | +0.54% | ||
| 1 month | -2.60% | ||
| 6 months | +0.54% | ||
| Current year | +1.26% |
1 week
27 750.00
28 200.00
1 month
27 600.0028 850.00
Current year
27 450.0029 650.00
1 year
25 500.0029 650.00
3 years
24 250.0034 350.00
5 years
21 950.0047 700.00
10 years
16 050.0052 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yoon-Woo Lee
CEO | Chief Executive Officer | 80 | 69-06-30 |
Dong-Il Lee
BRD | Director/Board Member | 71 | 02-02-28 |
Seong-Soo Yoon
AUD | Comptroller/Controller/Auditor | 46 | 17-03-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yoon-Woo Lee
CEO | Chief Executive Officer | 80 | 69-06-30 |
Seung-Young Lee
BRD | Director/Board Member | 51 | 02-02-28 |
Dong-Il Lee
BRD | Director/Board Member | 71 | 02-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-05 | 28,100 | +0.36% | 10,534 |
| 24-07-04 | 28,000 | 0.00% | 3,455 |
| 24-07-03 | 28,000 | 0.00% | 6,926 |
| 24-07-02 | 28,000 | -0.53% | 5,779 |
| 24-07-01 | 28,150 | +0.72% | 4,283 |
End-of-day quote Korea S.E., July 04, 2024
More quotes
DaehanPharmaceutical is a Korea-based company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. The Manufacturing Pharmaceutical segment is engaged in the manufacture and sale of pharmaceuticals such as infusion products, ampoules and vial products as well as others. The Other Sales segment is engaged in the provision of test inspection services.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.26% | 120M | |
| +24.53% | 45.07B | |
| +30.99% | 23.39B | |
| +24.13% | 16.08B | |
| +21.15% | 14.6B | |
| +68.67% | 14.01B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.53% | 5.64B | |
| +10.74% | 4.89B |
- Stock Market
- Equities
- A023910 Stock
